Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Schering Corporation

Praveen K Tadikonda

M Arshad Siddiqui

Timothy J Guzi

Lianyun Zhao

Gerald Wayne Shipps, Jr

Panduranga Adulla P Reddy

Tzu Tshin Wong

Thierry Olivier Fischmann

Binyuan Sun

David Benjamin Belanger

Jose S Duca

Luis E Torres

Patrick J Curran

Xiaohua Huang

Hongbo Zeng

Panduranga Adulla Reddy

Cliff C Cheng

Shuyi Tang

Matthew Richards

Blake Hamann

Joseph P Vacca

Craig Alan Coburn

Michael P Dwyer

Huw M Nash

Umar Faruk Mansoor

Kartik M Keertikar

Marc A Labroli

David Allen Annis

Thomas G Steele

Tong Wang

Gergely M Makara

David F Cauble, Jr

Cory S Poker

Marc M Labroli

Cory Poker

The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. 

Anilinopiperazine derivatives and methods of use thereof

The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. 

2-aminothiazole-4-carboxylic amides as protein kinase inhibitors

The present invention relates to novel heterocyclic amide compounds of Formula I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease. 

Heterocyclic amide compounds as protein kinase inhibitors

Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0. 

Substituted pyridines that are JNK inhibitors

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below: 

Imidazopyrazines as protein kinase inhibitors

The present invention is directed to phenyl carboxamide compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Growing community of inventors

Norwood, MA, United States of America

Praveen K Tadikonda